Clinical trial NCT03234907: Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.
Official title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Crohn's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Crohn's Disease
Keywords: Drug therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2017-07-31
Enrollment: 215
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety and efficacy of vedolizumab intravenous (IV) infusion as induction treatment in Chinese participants with moderately to severely active Crohn's disease (CD) at Week 10.

Detailed description: The drug being tested in this study is called vedolizumab. Vedolizumab will be administered as an intravenous (IV) infusion in Chinese participants. This study will investigate the efficacy and safety of vedolizumab IV as induction and maintenance therapy in participants with moderately to severely active Crohn's Disease (CD).

The study will enroll approximately 300 moderately to severely active Chinese patients with CD.

Induction Phase: participants will be randomized 2:1 to receive:

* Vedolizumab IV 300 mg
* Placebo IV

Participants will receive vedolizumab 300 mg or matching placebo, intravenous (IV) infusion at Weeks 0, 2, and 6 in the induction phase. At Week 10, participants will be assessed for clinical response. Results of Week 10 clinical response will determine the treatment pathway in the maintenance phase.

Maintenance Phase: participants who achieved clinical response at Week 10 will continue to receive the same treatment as they received in Induction Phase; every 8 weeks (Q8W) starting at Week 14. Participants who received vedolizumab IV or placebo in the Induction Phase and did not achieve clinical response at Week 10 will receive vedolizumab every 4 weeks (Q4W) starting at Week 14.

This multi-center trial will be conducted in China. The overall time to participate in this study is 60 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone, 6 months after last dose of study drug for a long-term follow-up safety survey.

Eligibility criteria: Inclusion Criteria:

1. Has a diagnosis of Crohn's disease (CD) established at least 3 months prior to Screening by clinical and endoscopic evidence corroborated by a histopathology report. Cases of CD established at least 6 months prior to randomization for which a histopathology report is not available will be considered based on the weight of evidence supporting the diagnosis and excluding other potential diagnosis, and must be discussed with the sponsor on a case-by-case basis prior to randomization.
2. Has moderately to severely active CD as determined by a Crohn's Disease Activity Index (CDAI) score of 220 to 400 within 7 days prior to the first dose of study drug and 1 of the following:

   * C-reactive protein (CRP) level \>2.87 mg/L during the Screening Phase, OR
   * Ileocolonoscopy with photographic documentation of a minimum of 3 nonanastomotic ulcerations (each \>0.5 cm in diameter) or 10 aphtous ulcerations (involving a minimum of 10 contiguous cm of intestine) consistent with CD, within 4 months prior to randomization, OR
   * Fecal calprotectin \>250 μg/g stool during the Screening Phase in conjunction with computed tomography enterography (CTE), magnetic resonance enterography (MRE), contrast enhanced small bowel radiography, or wireless capsule endoscopy revealing CD ulcerations (aphthae not sufficient), within 4 months prior to Screening
3. Has CD involvement of the ileum and/or colon, at a minimum.
4. Has extensive colitis or pancolitis of \>8 years duration or limited colitis of \>12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months prior to initial screening (may be performed during Screening if not performed in previous 12 months).
5. Has a family history of colorectal cancer, personal history of increased colorectal cancer risk, age \>50 years, or other known risk factor must be up-to-date on colorectal cancer surveillance (may be performed during Screening).
6. Has demonstrated an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents as defined below:

   * Corticosteroids.
   * Immunomodulators.
   * Tumor necrosis factor-alpha (TNF-α) antagonists.

Exclusion Criteria:

1. Has evidence of abdominal abscess at the initial Screening Visit.
2. Has had extensive colonic resection, subtotal or total colectomy.
3. Has a history of \>3 small bowel resections or diagnosis of short bowel syndrome.
4. Has had ileostomy, colostomy, known fixed symptomatic stenosis of the intestine, or evidence of fixed stenosis, or small bowel stenosis with prestenotic dilation.
5. Has had previous exposure to approved or investigational anti-integrins (e.g., natalizumab, efalizumab, etrolizumab, or AMG-181), or MAdCAM-1 antagonists, or rituximab.
6. Has used topical (rectal) treatment with 5-ASA, corticosteroid enemas/suppositories or traditional Chinese medications for CD treatment within 2 weeks of the administration of the first dose of study drug.
7. Requires currently or is anticipated to require surgical intervention for CD during the study.
8. Has a history or evidence of adenomatous colonic polyps that have not been removed.
9. Has a history or evidence of colonic mucosal dysplasia including low or high-grade dysplasia, as well as indeterminate for dysplasia.
10. Has a suspected or confirmed diagnosis of ulcerative colitis, indeterminate colitis, ischemic colitis, and radiation colitis.
11. Has evidence of treatment for C.difficile infection or other intestinal pathogen with 28 days prior to first dose of study drug.
12. Has chronic hepatitis B virus (HBV) infection or chronic hepatitis C virus (HCV) infection.
13. Has active or latent tuberculosis.
14. Has any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus \[HIV\] infection, organ transplantation).
15. Has any history of malignancy, except for the following: (a) adequately-treated nonmetastatic basal cell skin cancer; (b) squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to randomization; and (c) history of cervical carcinoma in situ that has been adequately treated and that has not recurred for at least 3 years prior to randomization. Participants with remote history of malignancy (e.g., \>10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and the therapy received and must be discussed with the sponsor on a case-by-case basis prior to randomization.
16. Has a history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
17. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist at Screening or prior to the administration of the first dose of study drug at Week 0.

Primary outcomes:
measure: Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10
timeFrame: Week 10
Secondary outcomes:
measure: Percentage of Participants With Clinical Remission in the Induction Phase at Week 10
timeFrame: Week 10
Other outcomes:
Locations:
city: Hefei
country: China
facility: Gastroenterology
state: Anhui
city: Beijing
country: China
facility: Gastroenterology
state: Beijing
city: Beijing
country: China
facility: Gastroenterology
state: Beijing
city: Chongqing
country: China
facility: Gastroenterology
state: Chongqing
city: Fuzhou
country: China
facility: Gastroenterology
state: Fujian
city: Xiamen
country: China
facility: Gastroenterology
state: Fujian
city: Guangzhou
country: China
facility: Gastroenterology
state: Guangdong
city: Guangzhou
country: China
facility: Gastroenterology
state: Guangdong
city: Guangzhou
country: China
facility: Gastroenterology
state: Guangdong
city: Wuhan
country: China
facility: Gastroenterology
state: Hubei
city: Wuhan
country: China
facility: Gastroenterology
state: Hubei
city: Wuhan
country: China
facility: Gastroenterology
state: Hubei
city: Changsha
country: China
facility: Gastroenterology
state: Hunan
city: Changsha
country: China
facility: Gastroenterology
state: Hunan
city: Changsha
country: China
facility: Gastroenterology
state: Hunan
city: Nanjing
country: China
facility: Gastroenterology
state: Jiangsu
city: Nanjing
country: China
facility: Gastroenterology
state: Jiangsu
city: Wuxi
country: China
facility: Gastroenterology
state: Jiangsu
city: Nanchang
country: China
facility: Gastroenterology
state: Jiangxi
city: Changchun
country: China
facility: Gastroenterology
state: Jilin
city: Shenyang
country: China
facility: Gastroenterology
state: Liaoning
city: Shanghai
country: China
facility: Gastroenterology
state: Shanghai
city: Shanghai
country: China
facility: Gastroenterology
state: Shanghai
city: Shanghai
country: China
facility: Gastroenterology
state: Shanghai
city: Shanghai
country: China
facility: Gastroenterology
state: Shanghai
city: Chengdu
country: China
facility: Gastroenterology
state: Sichuan
city: Kunming
country: China
facility: Gastroenterology
state: Yunnan
city: Hangzhou
country: China
facility: Gastroenterology
state: Zhejiang
city: Hangzhou
country: China
facility: Gastroenterology
state: Zhejiang
Study officials:
affiliation: Takeda
name: Study Director Clinical Science
role: STUDY_DIRECTOR
References: